PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma

American Journal of Clinical Pathology

Volumn 137, Issue 2, 2012, Pages 240-247

  Brenne, Kjersti ^a   Nymoen, Dag André ^a   Reich, Reuven ^b   Davidson, Ben ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Diagnosis; Malignant mesothelioma; M llerian carcinoma; PRAME; Preferentially expressed antigen of melanoma; Quantitative real time PCR; Serous effusions; Western blotting

Indexed keywords

MESSENGER RNA; PRAME PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; EFFUSION; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; METASTASIS; MIXED MULLERIAN TUMOR; OVARY CARCINOMA; PERITONEUM CANCER; PERITONEUM EFFUSION; PLEURA EFFUSION; PRAME GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION; HUMANS; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84856401870     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPGA95KVSAUDMF     Document Type: Article

References (39)

1. Davidson B. The biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog. 2007;13:189-227. (Pubitemid 351239093)
2. Davidson B. The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma. Cytopathology. 2011;22:5-21.
3. Davidson B, Zhang Z, Kleinberg L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006;12:5944-5950. (Pubitemid 44703753)
4. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6:199-208. (Pubitemid 27145564)
5. Tajeddine N, Gala JL, Louis M, et al. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res. 2005;65:7348-7355. (Pubitemid 41161267)
6. Gurevich I, Flores AM, Aneskievich BJ. Corepressors of agonist-bound nuclear receptors. Toxicol Appl Pharmacol. 2007;223:288-298. (Pubitemid 47362217)
7. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J Cell Physiol. 2011;226:322-330.
8. Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122:835-847. (Pubitemid 41345202)
9. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res. 2006;66:10639-10642. (Pubitemid 44876955)
10. Sigalotti L, Fratta E, Coral S, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res. 2004;64:9167-9171. (Pubitemid 39665532)
11. Soikkeli J, Lukk M, Nummela P, et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol. 2007;213:180-189. (Pubitemid 47612240)
12. Greiner J, Bullinger L, Guinn BA, et al. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res. 2008;14:7161-7166.
13. Wadelin F, Fulton J, McEwan PA, et al. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010;9:226. doi:10.1186/1476-4598-9-226.
14. Oberthuer A, Hero B, Spitz R, et al. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004;10:4307-4313. (Pubitemid 38878868)
15. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia. 2006;8:833-842. (Pubitemid 44564839)
16. Boon K, Edwards JB, Siu IM, et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene. 2003;22:7687-7694. (Pubitemid 37464103)
17. Li CM, Guo M, Borczuk A, et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol. 2002;160:2181-2190. (Pubitemid 34663409)
18. Biermann K, Heukamp LC, Steger K, et al. Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors. Cancer Genomics Proteomics. 2007;4:359-367. (Pubitemid 350067366)
19. Doolan P, Clynes M, Kennedy S, et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2008;109:359-365. (Pubitemid 351644842)
20. Epping MT, Hart AA, Glas AM, et al. PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008;99:398-403.
21. Sun Y, Urquidi V, Goodison S. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res Treat. 2010;119:593-599.
22. Smith SL, Bowers NL, Betticher DC, et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer. 2005;93:719-729. (Pubitemid 41486464)
23. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 1998;58:4090-4095. (Pubitemid 28440562)
24. Ringhoffer M, Müller CR, Schenk A, et al. Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy. J Urol. 2004;171:2456-2460. (Pubitemid 38625514)
25. Sarcevic B, Spagnoli GC, Terracciano L, et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology. 2003;64:443-449. (Pubitemid 36682960)
26. Figueiredo DL, Mamede RC, Proto-Siqueira R, et al. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck. 2006;28:614-619. (Pubitemid 44025110)
27. Cuffel C, Rivals JP, Zaugg Y, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer. 2011;128:2625-2634.
28. Schenk T, Stengel S, Goellner S, et al. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer. 2007;46:796-804. (Pubitemid 47106183)
29. Partheen K, Levan K, Osterberg L, et al. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006;42:2846-2854. (Pubitemid 44584671)
30. Partheen K, Levan K, Osterberg L, et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer. 2008;123:2130-2137.
31. Partheen K, Levan K, Osterberg L, et al. External validation suggests integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer. 2009;9:336. doi:10.1186/1471-2407-9-336.
32. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time"quantitative reverse-transcriptase polymerase reaction (RQ-PCR): a Europe Against Cancer program. Leukemia. 2003;17:2474-2486. (Pubitemid 38072587)
33. Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317-1331.
34. Yuan Y, Nymoen DA, Dong HP, et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol. 2009;40:1453-1460.
35. Bock AJ, Nymoen DA, Brenne K, et al. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions [published online ahead of print August 18, 2011]. Hum Pathol. doi:10.1016/j.humpath.2011.06.003.
36. Brenne K, Nymoen DA, Hetland TE, et al. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival [published online ahead of print August 18, 2011]. Hum Pathol. doi:10.1016/j.humpath.2011.05.023.
37. Yuan Y, Nymoen DA, Stavnes HT, et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol. 2009;33:1673-1682.
38. Yuan Y, Dong HP, Nymoen DA, et al. PINCH-2 expression in cancers involving serosal effusions using quantitative PCR. Cytopathology. 2011;22:22-29.
39. Davidson B. Anatomic site - related expression of cancer-associated molecules in ovarian carcinoma. Curr Cancer Drug Targets. 2007;7:109-120. (Pubitemid 46345512)